| Year |
Citation |
Score |
| 2022 |
Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, Haro-Acosta V, Das S, Steen CB, Pereira TA, Qian D, Beachy PA, Dirbas F, Red-Horse K, Rabbitts TH, et al. Identification of a minority population of LMO2 breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548. PMID 36351009 DOI: 10.1126/sciadv.abm3548 |
0.32 |
|
| 2020 |
Zabala M, Lobo NA, Antony J, Heitink LS, Gulati GS, Lam J, Parashurama N, Sanchez K, Adorno M, Sikandar SS, Kuo AH, Qian D, Kalisky T, Sim S, Li L, et al. LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis. Cell Stem Cell. PMID 32693087 DOI: 10.1016/J.Stem.2020.06.017 |
0.483 |
|
| 2020 |
Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, Ilagan F, Kuo AH, Hsieh RW, Cai S, Zabala M, Scheeren FA, Lobo NA, Qian D, Yu FB, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science (New York, N.Y.). 367: 405-411. PMID 31974247 DOI: 10.1126/Science.Aax0249 |
0.312 |
|
| 2018 |
Zabala M, Lobo NA, Seoane JA, Stelzer Y, Luong AV, Isobe T, Zarnegar MA, Watanabe N, Antoñana S, Lam J, Qian D, Sikandar SS, Kuo AH, Heitink LS, Shimono Y, et al. Abstract B67: The DLK1-DIO3 imprinted region regulates long-term proliferation in normal and malignant breast epithelium Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B67 |
0.344 |
|
| 2017 |
Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, Lobo NA, Scheeren FA, Sim S, Qian D, Dirbas FM, Somlo G, Quake SR, Clarke MF. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669. PMID 29162812 DOI: 10.1038/S41467-017-01666-2 |
0.416 |
|
| 2017 |
Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, Kuo AH, McKenna K, Kojima Y, Leeper NJ, Ho P, Gip P, Swigut T, Sherwood RI, Clarke MF, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature Communications. 8: 14802. PMID 28378740 DOI: 10.1038/Ncomms14802 |
0.303 |
|
| 2016 |
Cai S, Kalisky T, Sahoo D, Dalerba P, Feng W, Lin Y, Qian D, Kong A, Yu J, Wang F, Chen EY, Scheeren FA, Kuo AH, Sikandar SS, Hisamori S, et al. A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland. Cell Stem Cell. PMID 28041896 DOI: 10.1016/J.Stem.2016.11.007 |
0.365 |
|
| 2014 |
Kuo AH, Scheeren FA. Cell-intrinsic TLR2/MyD88 pathway in breast and colon cancer. Cell Cycle (Georgetown, Tex.). 13: 3785-6. PMID 25457615 DOI: 10.4161/15384101.2014.989947 |
0.365 |
|
| 2014 |
Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS, Lam JS, Qian D, Dirbas FM, Somlo G, Lao K, et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife. 3. PMID 25406066 DOI: 10.7554/Elife.01977 |
0.36 |
|
| 2014 |
Scheeren FA, Kuo AH, van Weele LJ, Cai S, Glykofridis I, Sikandar SS, Zabala M, Qian D, Lam JS, Johnston D, Volkmer JP, Sahoo D, van de Rijn M, Dirbas FM, Somlo G, et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. Nature Cell Biology. 16: 1238-48. PMID 25362351 DOI: 10.1038/Ncb3058 |
0.418 |
|
| 2014 |
Feng W, Gentles A, Nair RV, Huang M, Lin Y, Lee CY, Cai S, Scheeren FA, Kuo AH, Diehn M. Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells (Dayton, Ohio). 32: 1734-45. PMID 24497069 DOI: 10.1002/Stem.1662 |
0.354 |
|
| 2014 |
Kesler CT, Kuo AH, Wong HK, Masuck DJ, Shah JL, Kozak KR, Held KD, Padera TP. Vascular endothelial growth factor-C enhances radiosensitivity of lymphatic endothelial cells. Angiogenesis. 17: 419-27. PMID 24201897 DOI: 10.1007/S10456-013-9400-7 |
0.311 |
|
| 2014 |
Lee CY, Lin Y, Bratman SV, Feng W, Kuo AH, Scheeren FA, Engreitz JM, Varma S, West RB, Diehn M. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Research. 74: 341-52. PMID 24177178 DOI: 10.1158/0008-5472.Can-13-1055 |
0.387 |
|
| 2014 |
Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS, Lam JS, Qian D, Dirbas FM, Somlo G, Lao K, et al. Author response: miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway Elife. DOI: 10.7554/Elife.01977.019 |
0.359 |
|
| 2013 |
Kuo AH, Clarke MF. Identifying the metastatic seeds of breast cancer. Nature Biotechnology. 31: 504-5. PMID 23752434 DOI: 10.1038/Nbt.2599 |
0.333 |
|
| 2008 |
Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, Fukumura D, Jain RK. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Molecular Cancer Therapeutics. 7: 2272-9. PMID 18687659 DOI: 10.1158/1535-7163.Mct-08-0182 |
0.345 |
|
| 2007 |
Kuo AH, Stoica GE, Riegel AT, Wellstein A. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene. 26: 859-69. PMID 16878150 DOI: 10.1038/Sj.Onc.1209840 |
0.575 |
|
| 2006 |
Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Research. 66: 1191-8. PMID 16424058 DOI: 10.1158/0008-5472.Can-05-2926 |
0.514 |
|
| 2002 |
Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. The Journal of Biological Chemistry. 277: 35990-8. PMID 12122009 DOI: 10.1074/Jbc.M205749200 |
0.622 |
|
| 2001 |
Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. The Journal of Biological Chemistry. 276: 16772-9. PMID 11278720 DOI: 10.1074/Jbc.M010660200 |
0.629 |
|
| 1998 |
Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alamandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network Molecular and Cellular Biology. 18: 6090-6101. PMID 9742126 DOI: 10.1128/Mcb.18.10.6090 |
0.442 |
|
| 1998 |
Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen XH, Pierce JH. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proceedings of the National Academy of Sciences of the United States of America. 95: 6809-14. PMID 9618494 DOI: 10.1073/Pnas.95.12.6809 |
0.42 |
|
| 1998 |
Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y. Epiregulin is a potent Pan-ErbB ligand that preferentially activates heterodimeric receptor complexes Journal of Biological Chemistry. 273: 10496-10505. PMID 9553109 DOI: 10.1074/Jbc.273.17.10496 |
0.46 |
|
| 1997 |
Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. The Embo Journal. 16: 5608-17. PMID 9312020 DOI: 10.1093/Emboj/16.18.5608 |
0.429 |
|
| Show low-probability matches. |